Efgartigimod + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Sjögren's Syndrome
Conditions
Primary Sjögren's Syndrome
Trial Timeline
Apr 4, 2023 → Feb 12, 2024
NCT ID
NCT05817669About Efgartigimod + Placebo
Efgartigimod + Placebo is a phase 2 stage product being developed by Argenx for Primary Sjögren's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05817669. Target conditions include Primary Sjögren's Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Primary Sjögren's Syndrome were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05817669 | Phase 2 | Completed |
| NCT05633407 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Sjögren's Syndrome